Australian biotech market today 08.04.09
Wednesday, 08 April, 2009
The pharma and biotech index is down one per cent at 3pm today, in line with the rest of the All Ordinaries.
The Big Three – Cochlear (ASX:COH), CSL (ASX:CSL) and ResMed (ASX:RMD) – have followed the rest of the index and are down on today’s trading.
Pharmaxis (ASX:PXS), which yesterday appointed US-based life science investment manager Richard van den Broek to its board, is up 8c to almost $2.
Novogen (ASX:NRT) is also up again today on very small volumes. The company today announced good results from a Phase II trial being carried out by one of its US subsidiaries, Glycotex, in wound healing. While this trial is in a cosmetic application, the company is also investigating its compound GLYC-101 in burns, surgical wounds and venous and diabetic ulcers.
Progen (ASX:PGL) is up again despite its recent dramas, settling at just over 90c today.
API manufacturer IDT Australia (ASX:IDT) is down 6c to $1.52, while Circadian (ASX:CIR) is up 3c and Clinuvel (ASX:CLV) is up 1c.
Quitting smoking increases life expectancy even for seniors
Although the benefits of quitting smoking diminish with age, there are still substantial gains...
Stem cell transplants treat blindness in mini pigs
Scientists have successfully transplanted retinas made from stem cells into blind mini pigs,...
Sugary drinks raise cardiovascular disease risk, but occasional sweets don't
Although higher sugar intake raises your risk of certain cardiovascular diseases, consuming sweet...
